Aastrom Granted European Composition-of-Matter Patent for Ixmyelocel-T
04 October 2011 - 12:00AM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of
patient-specific, expanded multicellular therapies for the
treatment of severe, chronic cardiovascular diseases, today
announced that it has been granted a key composition of matter
patent from the European Patent Office. The patent provides
protection throughout the European Union for ixmyelocel-T, the
company's investigational product currently in clinical development
for the treatment of critical limb ischemia (CLI) and dilated
cardiomyopathy (DCM).
The issued patent, Mixed Cell Populations for Tissue Repair and
Separation Technique for Cell Processing, provides protection for
various claims regarding "an isolated cell composition…comprising a
mixed population of cells of hematopoietic, mesenchymal and
endothelial lineage," which characterizes the ixmyelocel-T
product. The company's patented single-pass perfusion
technology enables the production of ixmyelocel-T through selective
expansion of specific cell populations which have been shown in
preclinical and clinical studies to reduce inflammation (which
is associated with atherosclerotic vascular disease), remodel
ischemic tissue, and promote the formation of new blood
vessels.
"Together with the approval of a U.S. composition-of-matter
patent in January 2011, this key patent approval in the EU
significantly expands our intellectual property estate for
ixmyelocel-T. As we continue to advance ixmyelocel-T through
the final stages of clinical development, these patents provide
strong protection for our commercial interests and for future
global development and commercialization partners for
ixmyelocel-T," said Tim Mayleben, president and CEO of Aastrom
Biosciences.
This quarter, Aastrom plans to initiate a Phase 3 pivotal
clinical trial for ixmyelocel-T in the treatment of patients with
CLI who have no options for revascularization. The company also
plans to initiate a Phase 2b clinical trial for ixmyelocel-T in the
treatment of DCM in 2012.
About Aastrom Biosciences
Aastrom Biosciences is developing patient-specific, expanded
multicellular therapies for use in the treatment of severe, chronic
cardiovascular diseases. The company's proprietary cell-processing
technology enables the manufacture of ixmyelocel-T, a
patient-specific multicellular therapy expanded from a patient's
own bone marrow and delivered directly to damaged tissues. Aastrom
has advanced ixmyelocel-T into late-stage clinical development,
including a planned Phase 3 clinical program to study patients with
critical limb ischemia and two Phase 2 clinical trials in patients
with dilated cardiomyopathy. For more information, please visit
Aastrom's website at www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements, including,
without limitation, statements concerning clinical trial plans and
progress, objectives and expectations, clinical activity timing,
intended product development, the performance and contribution of
certain individuals and expected timing of collecting and analyzing
treatment data, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made
through the use of words or phrases such as "anticipates,"
"intends," "estimates," "plans," "expects," "we believe," "we
intend," and similar words or phrases, or future or conditional
verbs such as "will," "would," "should," "potential," "could,"
"may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent uncertainties associated with clinical
trial and product development activities, regulatory approval
requirements, competitive developments, and the availability of
resources and the allocation of resources among different potential
uses. These and other significant factors are discussed in greater
detail in Aastrom's Annual or Transition Report on Form 10-K or
10-K/T, Quarterly Reports on Form 10-Q and other filings with the
Securities and Exchange Commission. These forward-looking
statements reflect management's current views and Aastrom does not
undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date of this release except as required by law.
CONTACT: Media contact
Bill Berry
Berry & Company
bberry@berrypr.com
(212) 253-8881
Investor contact
Danielle Spangler
The Trout Group
dspangler@troutgroup.com
(646) 378-2924
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2024 to Aug 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Aug 2023 to Aug 2024